Virtual Library
Start Your Search
Z. Zhou
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-006 - Propensity Score Matched Comparison of EGFR TKI for EGFR Mutation 19del vs 21L858R (ID 2319)
09:30 - 09:30 | Author(s): Z. Zhou
- Abstract
Background:
Previously, data of Lux-lung 3 and Lux-lung 6 showed overall survival was improved with the afatinib for patients with 19del EGFR mutations and the absence of an effect in patients with L858R EGFR mutations suggests that EGFR 19del-positive disease might be distinct from L858R-positive disease. We aimed to assess the effect of first-generation reverse EGFR TKI (Gefitinib and Elotinib) on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from real world practice.
Methods:
This is a retrospective study, 134 patients with EGFRm 19del or 21L858R with reverse EGFR TKI gefitinib or elotinib in clinical practice from Jun.2012 to April.2014 in Shanghai Chest Hospital , follow-up to April.1,2015. To control for selection bias, matched groups of patients were selected using a propensity score matching method. Overall survival and PFS were estimated using the Kaplan-Meier method with log-rank test. The Wilcoxon rank sum test was used for variables not normally distributed. Categorical data are displayed as frequencies and comparisons were made with Chi-square tests (Fisher exact tests if appropriate).
Results:
After1:1 the propensity score matching, matching was based on a one-to-two nearest neighbor matching method with a tolerance level on the maximum propensity score distance (calipers of width 0.2 standard deviation of the logit of the PS). 70 patients were enrolled, the baseline variables (eg, age, sex, smoking , PS, line of EGFR TKI treatment ) were comparable between the matched cohorts (P > 0.05 for all). Follow-up time: 19del (median 16.2 months, range 1.0-49.2) , 21L858R (median 16.4 months, range 0.4-41.1). m PFS in 19 del and 21L858R was 16.3months, 16.8months, respectively, m OS in 19 del and 21L858R was28.4 months, 32.2 months, respectively, There are no significant difference between EGFR mutation 19del and 21L858R patients with the reversible first-generation inhibitors.
Conclusion:
CONCLUSION: There are no significant difference between EGFR mutation 19del and 21L858R patients with the reversible first-generation inhibitors either PFS or OS. The results maybe related to the sample size, waiting for the results of meta-analysis.
